Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2197663 | Molecular and Cellular Endocrinology | 2008 | 5 Pages |
Abstract
Somatostatin has been discovered as a somatotroph release inhibitory factor (SRIF), and, indeed, it has been demonstrated that SRIF and its analogs can inhibit pituitary tumor hormone secretion and control neoplastic bulk. Several in vitro studies have contributed to the current knowledge of the mechanisms by which SRIF and its analogs may influence pituitary adenomas, opening the way to new possible therapeutic strategies.This review focuses on the results obtained by testing several SRIF analogs in vitro on pituitary adenomas, concerning both secretory activity and cell viability. These studies provide the basis for further investigations, both at basic and clinical level, of the application of SRIF analogs in the pituitary field.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Maria Chiara Zatelli, Maria Rosaria Ambrosio, Marta Bondanelli, Ettore C. degli Uberti,